Nameera Temkar, MD

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment options.

Genetic variability and sex-specific differences may play a role in sickle cell disease (SCD)-related pain; however, more research is needed.

Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.

A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.